NCT02332954 - Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine | Biotech Hunter

Enrollment

226

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

July 6, 2017

Study Completion Date

July 6, 2017

Conditions

Major Depressive Disorder

Interventions

DRUG

vortioxetine

The starting and recommended dose of vortioxetine is 10 mg once daily; film-coated 10 mg tablets for oral use once daily for 52 weeks.Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily.

Trial Locations (26)

T6L 6W6

CA004, Edmonton

V1Y 1Z9

CA005, Kelowna

A1E 2C2

CA006, St. John's

B3S 1M7

CA007, Halifax

L7R 4E2

CA016, Burlington

N7L 1C1

CA013, Chatham

N0N 1G0

CA010, Corunna

L2A 1Z3

CA012, Fort Erie

L8M 1K7

CA017, Hamilton

L8N 4A6

CA026, Hamilton

N6H 4P2

CA011, London

L5M 4N4

CA003, Mississauga

N7T 4X3

CA008, Sarnia

CA009, Sarnia

L2T 3Y4

CA015, St. Catharines

H1N 3V2

CA022, Montreal

H2R 1V6

CA020, Montreal

H3A 0G6

CA023, Montreal

H9R 4S3

CA018, Pointe-Claire

J2W 1J1

CA024, Saint-Jean-sur-Richelieu

G6P 6P6

CA030, Victoriaville

H4A1S9

CA027, Westmount

S7K 3H3

CA028, Saskatoon

G1G 3Y8

CA019, Québec

G3K 2P8

CA021, Québec

CA029, Québec

All Listed Sponsors

lead

Lundbeck Canada Inc.

INDUSTRY